Drug Profile
FP 045
Alternative Names: FP-045Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator Foresee Pharmaceuticals
- Class Antianaemics; Cardiovascular therapies; Hepatoprotectants; Small molecules
- Mechanism of Action Aldehyde dehydrogenase 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Fanconi's anaemia
- Phase I Cardiovascular disorders; Kidney disorders; Metabolic disorders; Pulmonary hypertension
- No development reported Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 30 Oct 2023 Foresee Pharmaceuticals plans a phase II WINDWARD trial in pulmonary hypertension-interstitial lung disease (PH-ILD) in 2024
- 12 Oct 2023 FP 045 is still in phase-I trials for Cardiovascular disorders in USA (Foresee Pharmaceutical pipeline; October 2023)
- 12 Oct 2023 Phase-I clinical trials in Kidney disorders in USA (PO) (Foresee Pharmaceutical pipeline; October 2023)